141 related articles for article (PubMed ID: 17577624)
21. Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy.
Tabuse H; Kashiwagi H; Hamauchi S; Tsushima T; Todaka A; Yokota T; Machida N; Yamazaki K; Fukutomi A; Onozawa Y; Mori K; Boku N; Ichinose M; Yasui H
Gastric Cancer; 2016 Jul; 19(3):894-901. PubMed ID: 26362271
[TBL] [Abstract][Full Text] [Related]
22. [Results of treatment of far advanced and recurrent stomach cancer with TS-1].
Johira H; Yunoki S; Kawata N; Watanabe N; Hachisuka Y; Kimura M; Uomoto M; Hatano H; Sanada E; Watanabe R; Ohmori K; Miyata N
Gan To Kagaku Ryoho; 2005 Feb; 32(2):195-9. PubMed ID: 15751632
[TBL] [Abstract][Full Text] [Related]
23. Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding.
Fujitani K; Tsujinaka T; Hirao M
Hepatogastroenterology; 2003; 50(51):889-92. PubMed ID: 12828112
[TBL] [Abstract][Full Text] [Related]
24. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination.
Osugi H; Takada N; Takemura M; Kaseno S; Lee S; Ueno M; Tanaka Y; Fukuhara K; Fujiwara Y; Kinoshita H
Oncol Rep; 2002; 9(4):811-5. PubMed ID: 12066214
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
Arai K; Iwasaki Y; Kimura Y; Takahashi K; Yamaguchi T; Honma S; Takahashi T
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1297-301. PubMed ID: 14518409
[TBL] [Abstract][Full Text] [Related]
26. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
[TBL] [Abstract][Full Text] [Related]
27. [S-1 for gastric cancer-S-1 monotherapy and its progress].
Shitara K; Sakata Y; Kudou T; Munakata M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():43-51. PubMed ID: 16897971
[TBL] [Abstract][Full Text] [Related]
28. [Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer].
Ohshima T; Yamada R; Hatori S; Kunisaki C; Makino T; Yamazaki Y; Suda T; Rino Y; Takanashi Y; Imada T
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1105-10. PubMed ID: 16912529
[TBL] [Abstract][Full Text] [Related]
29. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Saeki T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Taguchi T
Gan To Kagaku Ryoho; 2004 Apr; 31(4):539-47. PubMed ID: 15114697
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Ito Y; Osaki Y; Tokudome N; Sugihara T; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2009; 16(2):126-31. PubMed ID: 18807123
[TBL] [Abstract][Full Text] [Related]
31. [A case of liver metastasis of gastric cancer responding well to TS-1].
Niinobu T; Yamamoto M; Taniguchi M; Kotobuki T; Otsuka A
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1674-7. PubMed ID: 15553680
[TBL] [Abstract][Full Text] [Related]
32. [Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].
Takebayashi K; Kawai Y; Tagi T; Matsumura M; Shimizu K; Yamamoto H; Mekata E; Tani T; Sato M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):385-7. PubMed ID: 22421764
[TBL] [Abstract][Full Text] [Related]
33. [The feasibility of oral fluoropyrimidines as adjuvant chemotherapy after resection and local coagulation therapy of colorectal liver metastases].
Narita T; Seshimo A; Itabashi M; Aratake K; Ogawa S; Hirosawa T; Hashimoto T; Amano K; Kameoka S
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1821-4. PubMed ID: 22083190
[TBL] [Abstract][Full Text] [Related]
34. [A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital].
Abe S; Kojima M; Tamura H; Kurihara H; Kitago M; Kobayashi T; Nakamura T; Ogihara T
Gan To Kagaku Ryoho; 2003 Jul; 30(7):963-70. PubMed ID: 12894711
[TBL] [Abstract][Full Text] [Related]
35. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
Blum M; Suzuki A; Ajani JA
Future Oncol; 2011 Jun; 7(6):715-26. PubMed ID: 21675835
[TBL] [Abstract][Full Text] [Related]
36. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
[TBL] [Abstract][Full Text] [Related]
37. [The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination].
Inaba Y; Watabe S; Ohe S; Kamio Y; Koyama M; Hayashi K; Chiba M
Gan To Kagaku Ryoho; 2002 Feb; 29(2):239-44. PubMed ID: 11865630
[TBL] [Abstract][Full Text] [Related]
38. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
[TBL] [Abstract][Full Text] [Related]
39. S-1 (Teysuno®): a review of its use in advanced gastric cancer in non-Asian populations.
Sanford M
Drugs; 2013 Jun; 73(8):845-55. PubMed ID: 23719766
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer.
Sakaguchi Y; Kabashima A; Okita K; Ojima Y; Yamamura S; Nishizaki T; Tashiro H; Matsusaka T
Gastric Cancer; 2005; 8(2):111-6. PubMed ID: 15864718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
